Omnimmune Holdings, Inc. (OMMH)

0.0001 0.0000 (0.00%) At close: 09:35AM EDT

Omnimmune Holdings, Inc.

4600 Post Oak Place
Suite 352
Houston, TX 77027
United States
713-622-8400

Sector(s): 
Industry: 
Full-time employees: 2

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Howard Becker	Chief Operating Officer	4k	N/A	1959
Dr. Alexander Krichevsky D.V.M	Vice President, Director of Research and Director	N/A	N/A	1948

Amounts are as of 31 December 2008, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States. The company owns rights for monoclonal antibody technologies. It also intends to develop personalized cancer treatment with the selection of prophylactic and therapeutic vaccines (active immunization), monoclonal antibodies (passive immunization), and genomic-based products, which target a hormone called human chorionic gonadotropin. In addition, the company plans to conduct a Phase I trial with its lead candidate anti-human chorionic gonadotropin beta subunit monoclonal antibodies based upon the results of the diagnostic trial. Omnimmune Holdings, Inc. is based in Houston, Texas.

Corporate governance

Omnimmune Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.